购物车
- 全部删除
- 您的购物车当前为空
TGF beta 1 Protein, Human/Rhesus/Cynomolgus/Canine, Recombinant is expressed in CHO mammalian cells. The predicted molecular weight is 12.8 kDa and the accession number is A0A499FJK2.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
20 μg | ¥ 1,950 | 现货 | |
100 μg | ¥ 4,930 | 5日内发货 | |
200 μg | ¥ 8,220 | 5日内发货 | |
500 μg | ¥ 16,130 | 5日内发货 |
生物活性 | 1. Measured by its ability to inhibit cell proliferation of Mv-1-lu mink lung epithelial cells. The ED50 for this effect is typically 0.01-0.1 ng/mL. _x000D_ 2. Human liver cancer organoids were cultured with FGF2 (Cat#TMPY-00749), HGF (Cat#TMPY-02327), FGF7 (Cat#TMPY-00403), EGF (Cat#TMPY-03701), FGF10 (Cat#TMPY-01061), TGFB1 (Cat#TMPY-02638), NOG (Cat#TMPY-02594), RSPO1 (Cat#TMPY-03626). |
产品描述 | TGF beta 1 Protein, Human/Rhesus/Cynomolgus/Canine, Recombinant is expressed in CHO mammalian cells. The predicted molecular weight is 12.8 kDa and the accession number is A0A499FJK2. |
种属 | Human,Rhesus,Cynomolgus,Canine |
表达系统 | CHO Cells |
标签 | Tag Free |
蛋白编号 | P01137 |
别名 | 转化生长因子,transforming growth factor, β1,transforming growth factor, beta 1,TGF β1 |
蛋白构建 | A DNA sequence encoding the active form of human / rhesus / cynomolgus / canine TGFβ1 (NP_000651.3) (Ala 279-Ser 390) was expressed and purified. Human, Rhesus, cynomolgus and Canine TGFβ1 sequences are identical. Predicted N terminal: Ala 279 |
蛋白纯度 | > 95 % as determined by SDS-PAGE. |
分子量 | 12.8 kDa (predicted); 13 & 26 kDa (non-reducing conditions) |
内毒素 | < 1.0 EU/μg of the protein as determined by the LAL method. |
缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing 100 mM GLY, 10 mM NaCl, pH 3. 0.Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
复溶方法 | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. |
研究背景 | TGF-beta 1 is a member of the transforming growth factor beta (TGF-beta) family. The transforming growth factor-beta family of polypeptides are involved in the regulation of cellular processes, including cell division, differentiation, motility, adhesion and death. TGF-beta 1 positively and negatively regulates many other growth factors. It inhibits the secretion and activity of many other cytokines including interferon-γ, tumor necrosis factor-alpha and various interleukins. It can also decrease the expression levels of cytokine receptors. Meanwhile, TGF-beta 1 also increases the expression of certain cytokines in T cells and promotes their proliferation, particularly if the cells are immature. TGF-beta 1 also inhibits proliferation and stimulates apoptosis of B cells, and plays a role in controlling the expression of antibody, transferrin and MHC class II proteins on immature and mature B cells. As for myeloid cells, TGF-beta 1can inhibit their proliferation and prevent their production of reactive oxygen and nitrogen intermediates. However, as with other cell types, TGF-beta 1 also has the opposite effect on cells of myeloid origin. TGF-beta 1 is a multifunctional protein that controls proliferation, differentiation and other functions in many cell types. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Once cells lose their sensitivity to TGF-beta1-mediated growth inhibition, autocrine TGF-beta signaling can promote tumorigenesis. Elevated levels of TGF-beta1 are often observed in advanced carcinomas, and have been correlated with increased tumor invasiveness and disease progression.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.